GINGER SHUPE: Open Payments
NPI 1689931115 · SOUTH MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$27,907 in 135 payments from 12 companies in 2025. Trend: 2023 $902 · 2024 $17,590 · 2025 $27,907
Speaker / faculty: $13,500Consulting: $7,870Food & beverage: $4,488Travel & lodging: $1,938Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $14,117 |
| E.R. Squibb & Sons, L.L.C. | 29 | $10,742 |
| Teva Pharmaceuticals USA, Inc. | 19 | $924 |
| Neurocrine BioSciences, Inc. | 19 | $719 |
| Otsuka America Pharmaceutical, Inc. | 13 | $475 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $288 |
| Luye Pharma (USA) Ltd. | 3 | $161 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Alkermes, Inc. | 5 | $118 |
| Lundbeck LLC | 5 | $114 |
Products named: VRAYLAR, COBENFY, INGREZZA, AUSTEDO XR, REXULTI, CAPLYTA, UZEDY, ERZOFRI EXTENDED-RELEASE.
Industry payments across FL — which companies pay providers there.
